Wegovy

Wegovy is Novo Nordisk’s once-weekly semaglutide GLP-1 receptor agonist approved for chronic weight management. It reduces appetite and slows gastric emptying, producing substantial weight loss in trials. Unlike Equator’s mitochondrial thermogenesis approach, it does not increase calorie burn at rest and requires ongoing injections with common GI side effects. Pricing is subscription-based through specialty pharmacies.